Hawaii Administrative Rules › Title 11 - DEPARTMENT OF HEALTH › Subtitle 1 - GENERAL DEPARTMENTAL PROVISIONS › Chapter 266.1 - HAZARDOUS WASTE MANAGEMENT: STANDARDS FOR THE MANAGEMENT OF SPECIFIC HAZARDOUS WASTES AND SPECIFIC TYPES OF HAZARDOUS WASTE MANAGEMENT FACILITIES › Part 266 - STANDARDS FOR THE MANAGEMENT OF SPECIFIC HAZARDOUS WASTES AND SPECIFIC TYPES OF HAZARDOUS WASTE MANAGEMENT FACILITIES › Subpart P - Hazardous Waste Pharmaceuticals and Hazardous Waste Electronic Nicotine Delivery Systems › Section 11-266.509 - Shipping potentially creditable hazardous waste pharmaceuticals from a healthcare facility or a reverse distributor to a reverse distributor

Current through June, 2024
(a) Shipping potentially creditable hazardous
					 waste pharmaceuticals. A healthcare facility or a reverse distributor who
					 transports or offers for transport potentially creditable hazardous waste
					 pharmaceuticals offsite to a reverse distributor must comply with all
					 applicable U.S. Department of Transportation regulations in 49 CFR part 171
					 through 180 for any potentially creditable hazardous waste pharmaceutical that
					 meets the definition of hazardous material in
					 49 CFR
					 171.8. For purposes of the Department of
					 Transportation regulations, a material is considered a hazardous waste if it is
					 subject to the Hazardous Waste Manifest Requirements of the U.S. Environmental
					 Protection Agency specified in 40 CFR part 262 [federal]. Because a potentially
					 creditable hazardous waste pharmaceutical does not require a manifest, it is
					 not considered hazardous waste under the Department of Transportation
					 regulations.
(b) Delivery
					 confirmation. Upon receipt of each shipment of potentially creditable hazardous
					 waste pharmaceuticals, the receiving reverse distributor must provide
					 confirmation (paper or electronic) to the healthcare facility or reverse
					 distributor that initiated the shipment that the shipment of potentially
					 creditable hazardous waste pharmaceuticals has arrived at its destination and
					 is under the custody and control of the reverse distributor.
(c) Procedures for when delivery confirmation
					 is not received within 35 calendar days. If a healthcare facility or reverse
					 distributor initiates a shipment of potentially creditable hazardous waste
					 pharmaceuticals to a reverse distributor and does not receive delivery
					 confirmation within 35 calendar days from the date that the shipment of
					 potentially creditable hazardous waste pharmaceuticals was sent, the healthcare
					 facility or reverse distributor that initiated the shipment must contact the
					 carrier and the intended recipient (i.e., the reverse distributor) promptly to
					 report that the delivery confirmation was not received and to determine the
					 status of the potentially creditable hazardous waste pharmaceuticals.
(d) Exporting potentially creditable
					 hazardous waste pharmaceuticals. A healthcare facility or reverse distributor
					 that sends potentially creditable hazardous waste pharmaceuticals to a foreign
					 destination must comply with the applicable sections of 40 CFR part 262 subpart
					 H, except the manifesting requirement of § 262.83(c), in addition to
					 paragraphs (a) through (c) of this section.
(e) Importing potentially creditable
					 hazardous waste pharmaceuticals. Any person that imports potentially creditable
					 hazardous waste pharmaceuticals into the United States is subject to paragraphs
					 (a) through (c) of this section in lieu of 40 CFR part 262 subpart H.
					 Immediately after the potentially creditable hazardous waste pharmaceuticals
					 enter the United States, they are subject to all applicable requirements of
					 this subpart.